Yourgene climbs as revenues surge

AIM-listed molecular diagnostics specialist Yourgene (LON:YGEN) has seen its share price rise by 5.65% to 12.15p (as of 12:15 BST) as revenues rose by 98% for the six months ended 30th September. The bulk of this improvement came from markets outside the UK.

CEO Lyn Rees commented: “I am delighted with the performance in the first half, both in terms of the organic growth delivered but also the contribution from the Elucigene acquisition and the launch of our American business. We are executing on our strategy to broaden our product portfolio and to drive growth across wider international markets. We remain on track to hit our ambitious growth targets for the enlarged Group and to meet market expectations for the full year“.